Shares in Dr.Reddy's Laboratories gain 2.1 percent after the company on Thursday said in a statement that it launched Zenatane, a generic version of Accutane drug, following its approval by the United States Food & Drug Administration.
Shares in Dr.Reddy's Laboratories
The company added that the drug had USD 309 million in sales for the most recent twelve months ending January 2013, according to IMS Health.
"Assuming an incremental 20-25 percent price drop and 20 percent market share, this could be USD 50 million per year revenue opportunity for Dr.Reddy's," Morgan Stanley said in a report.
Dr Reddys Labs stock price
On September 01, 2015, Dr Reddys Laboratories closed at Rs 4253.35, down Rs 56.8, or 1.32 percent. The 52-week high of the share was Rs 4337.00 and the 52-week low was Rs 2883.40.
The company's trailing 12-month (TTM) EPS was at Rs 91.02 per share as per the quarter ended June 2015. The stock's price-to-earnings (P/E) ratio was 46.73. The latest book value of the company is Rs 623.49 per share. At current value, the price-to-book value of the company is 6.82.
READ MORE ON Dr.Reddy's Laboratories
Set email alert for
ADS BY GOOGLE
video of the day
No one doubts India; rate cut lurking: Motilal Oswal